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z Evidence summary
VVC is a common cause of vaginitis; Can-
dida albicans accounts for 85% to 90% 
of cases. Risk factors include pregnancy, 
diabetes mellitus, and systemic antibiot-
ics.1 Incidence increases with onset of sex-
ual activity, but there is no direct evidence 
it is sexually transmitted.1 About 75% of 
women experience 1 VVC episode dur-
ing their lifetime, 40% to 45% have 2 or 
more, and 5% to 8% have recurrent VVC 
(defined as 4 or more annually).1,2
The candidiasis/antibiotics link
A 2003 systematic review found the evi-
dence supporting the association between 
antibiotics and VVC limited and contra-
dictory.3 Most were case-control or co-
hort studies with small sample sizes. No 
RCTs compare the incidence of culture-
confirmed VVC among women receiving 
antibiotics or placebo. 
Nineteen reports of 18 original studies 
had sufficient data to calculate a relative 
risk or odds ratio for antibiotic-associated 
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oral	and	intravaginal	antifungals	
for	the	treatment	of	uncomplicated	
vulvovaginal	candidiasis	(vvC)	have	similar	
effectiveness	(strength	of	recommendation	
[sor]:	A,	systematic	review).	However,	
no	randomized	controlled	trials	(rCts)	
have	addressed	treatment	options	for	
patients	taking	antibiotics.	oral	antifungals	
are	contraindicated	in	pregnancy.	While	
shorter	courses	of	intravaginal	therapy	
can	be	used	by	nonpregnant	women,	
7-day	treatment	may	be	necessary	during	
pregnancy	(sor:	A,	systematic	review).	
Products	containing	Lactobacillus	species	
do	not	prevent	postantibiotic	vulvovaginitis	
(sor:	A,	systematic	review	and	rCt).	
Most women would rather  
prevent than treat
Many	women	complain	about	getting	
yeast	infections	after	receiving	antibiotics.	
usually	the	patient	will	inform	me	of	this	
while	I’m	writing	the	prescription	for	the	
antibiotic,	asking	for	Diflucan	“just	in	
case.”	Women	prefer	the	convenience	
of	the	oral	medicine	over	the	hassle	with	
topical	applications.	some	state	that		
1	dose	of	Diflucan	does	not	cut	it,	and	
that	they	usually	need	2.	As	a	result,	I	find	
myself	writing	a	prescription	for	Diflucan	
to	be	started	along	with	the	antibiotic,	and	
then	to	be	repeated	as	a	second	dose	in	
3	days.	I	have	not	heard	any	complaints	
from	these	patients	about	postantibiotic	
yeast	infections.	
laura Kittinger-aisenberg, MD
Chesterfield	Family	Medicine	residency	Program,	
virginia	Commonwealth	university
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Both oral and 
topical antifungals 
have clinical cure 
rates >80%
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VVC. Thirteen of the 19 reports showed 
an increase (around twofold; range, 0.43–
5) in vaginal Candida prevalence; howev-
er, 3 of the 13 reports had no mycological 
culture data. Six studies did not show sig-
nificant association between antibiotics 
and vaginal yeast.3
Antibiotics are thought to increase 
risk of VVC by killing endogenous vagi-
nal flora (particularly Lactobacillus), al-
lowing microorganisms resistant to the 
antibiotics, like Candida, to flourish.1 Yet 
there is evidence that numbers of genital 
Lactobacillus are similar for women with 
and without symptomatic VVC.4 Further, 
decreasing Lactobacillus does not increase 
the risk of VVC.5 
Topical and oral antifungals—  
both do the job
For the treatment of uncomplicated 
VVC, both topical and oral antifungals 
are clinically and mycologically effec-
tive, with comparable clinical cure rates 
>80%.6 No difference in persistent symp-
toms between single and multiple doses, 
or different durations of multiple dose 
regimens have been found, but samples 
may have been too small to detect clini-
cally significant effects. An RCT found 
less nausea, headache, and abdominal 
pain with intravaginal imidazoles, but 
more vulvar irritation and vaginal dis-
charge than oral fluconazole.6 
For treatment of recurrent VVC, 
RCTs have shown the effectiveness of oral 
fluconazole and itraconazole maintenance 
therapy taken for 6 months after an initial 
regimen.7,8 Treating male sexual partners 
did not significantly improve resolution of 
the woman’s symptoms or reduce the rate 
of symptomatic relapse.9
Yogurt may not live up to its rep 
Two poor-quality crossover RCTs provid-
ed insufficient evidence regarding effec-
tiveness of a diet containing oral Lactoba-
cillus yogurt to prevent recurrent VVC.9 
A recent RCT of 278 women on short 
courses of antibiotics were randomized 
to oral lactobacilli or placebo and vaginal 
lactobacilli or placebo.10 The study was 
stopped early because there was no effect 
seen. Overall, 23% developed symptom-
atic vulvovaginitis. 
Recommendations from others
The Infectious Diseases Society of Ameri-
ca11 recommends treating uncomplicated 
VVC with short-course of oral or topical 
antifungals; treating complicated VVC 
with antimycotic therapy for 7 days, ei-
ther daily as topical therapy or as two 
150-mg doses of fluconazole 72 hours 
apart; treating non-albicans species of 
Candida with topical boric acid (600 mg/
day for 14 days) or topical flucytosine; 
and treating recurrent VVC with induc-
tion therapy with 2 weeks of a topical 
or oral azole followed by a maintenance 
regimen for 6 months (fluconazole once a 
week or itraconazole twice a week).11  n
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